Electronegative low-density lipoprotein. A link between apolipoprotein B misfolding, lipoprotein aggregation and proteoglycan binding

Current Opinion in Lipidology

Volumn 23, Issue 5, 2012, Pages 479-486

  Sánchez Quesada, José L ^a   Villegas, Sandra ^b   Ordóñez Llanos, Jordi ^a,b  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

apoB structure; LDL aggregation; phospholipase C; proteoglycans; sphingomyelinase

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE C; PROTEOGLYCAN;

AMINO TERMINAL SEQUENCE; ATHEROGENESIS; BLOOD; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; HUMAN; IMMUNOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN STRUCTURE; REVIEW;

APOLIPOPROTEINS B; ATHEROSCLEROSIS; CIRCULAR DICHROISM; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPOPROTEINS; LIPOPROTEINS, LDL; MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEOGLYCANS; TYPE C PHOSPHOLIPASES;

EID: 84866320576     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328357c933     Document Type: Review

References (49)

1. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9:471-474. (Pubitemid 28495557)
2. Pentikainen MO, Oorni K, Ala-Korpela M, Kovanen PT. Modified LDL-trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med 2000; 247:359-370. (Pubitemid 30180038)
3. Sanchez-Quesada JL, Benitez S, Otal C, et al. Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects. J Lipid Res 2002; 43:699-705. (Pubitemid 34477896)
4. Sanchez-Quesada JL, Benitez S, Ordonez-Llanos J. Electronegative low-density lipoprotein. Curr Opin Lipidol 2004; 15:329-335. (Pubitemid 38716567)
5. Mello AP, da Silva IT, Abdalla DS, Damasceno NR. Electronegative low-density lipoprotein: origin and impact on health and disease. Atherosclerosis 2011; 215:257-265.
6. Pentikainen MO, Oörni K, Kovanen PT. Myeloperoxidase and hypochlorite, but not copper ions, oxidize heparin-bound LDL particles and release them from heparin. Arterioscler Thromb Vasc Biol 2001; 21:1902-1908. (Pubitemid 34219739)
7. Abe Y, Fornage M, Yang CY, et al. L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion. Atherosclerosis 2007; 192:56-66. (Pubitemid 46628805)
8. Benitez S, Camacho M, Bancells C, et al. Wide proinflammatory effect of electronegative low-density lipoprotein on human endothelial cells assayed by a protein array. Biochim Biophys Acta 2006; 1761:1014-1021. (Pubitemid 44354285)
9. Benitez S, Perez A, Sanchez-Quesada JL, et al. Electronegative low-density lipoprotein subfraction from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control. Diabetes Metab Res Rev 2007; 23:26-34. (Pubitemid 46152483)
10. DeCastellarnau C, Bancells C, Benitez S, et al. Atherogenicand inflammatory profile of human arterial endothelial cells (HUAEC) in response to LDL subfractions. Clin Chim Acta 2007; 376:233-236. (Pubitemid 44880988)
11. Lu J, Jiang W, Yang JH, et al. Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes 2008; 57:158-166.
12. Lu J, Yang JH, Burns AR, et al. Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apop-tosis. Circ Res 2009; 104:619-627.
13. Tang D, Lu J, Walterscheid JP, et al. Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. J Lipid Res 2008; 49:33-47.
14. Yang CY, Chen HH, Huang MT, et al. Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. Atherosclerosis 2007; 193:283-291. (Pubitemid 47064401)
15. Ziouzenkova O, Asatryan L, Sahady D, et al. Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem 2003; 278:39874-39881. (Pubitemid 37248550)
16. Pedrosa AM, Faine LA, Grosso DM, et al. Electronegative LDL induction of apoptosis in macrophages: involvement of Nrf2. Biochim Biophys Acta 2010; 1801:430-437.
17. Parasassi T, Bittolo-Bon G, Brunelli R, et al. Loss of apoB-100 secondary structure and conformation in hydroperoxide rich, electronegative LDL(\). Free Radic Biol Med 2001; 31:82-89. (Pubitemid 32568427)
18. Parasassi T, De Spirito M, Mei G, et al. Low density lipoprotein misfolding and amyloidogenesis. FASEB J 2008; 22:2350-2356. (Pubitemid 351948653)
19. Greco G, Balogh G, Brunelli R, et al. Generation in human plasma of misfolded, aggregation-prone electronegative low density lipoprotein. Biophys J 2009; 97:628-635.
20. Brunelli R, Balogh G, Costa G, et al. Estradiol binding prevents ApoB-100 misfolding in electronegative LDL(\). Biochemistry 2010; 49:7297-7302.
21. Asatryan L, Hamilton RT, Isas JM, et al. LDLphospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein. J Lipid Res 2005; 46:115-122. (Pubitemid 40066677)
22. Bancells C, Benitez S, Villegas S, et al. Novel phospholipolytic activities associated with electronegative low-density lipoprotein are involved in increased self-aggregation. Biochemistry 2008; 47:8186-8194.
23. Bancells C, Benitez S, Jauhiainen M, et al. High binding affinity of electronegative LDL to human aortic proteoglycans depends on its aggregation level. J Lipid Res 2009; 50:446-455.
24. Blanco FJ, Villegas S, Benitez S, et al. 2D-NMR reveals different populations of exposed lysine residues in the apoB-100 protein of electronegative and electropositive fractions of LDL particles. J Lipid Res 2010; 51:1560-1565.
25. Bancells C, Benitez S, Ordonez-Llanos J, et al. Immunochemical analysis of the electronegative LDL subfraction shows that abnormal N-terminal apoli-poprotein B conformation is involved in increased binding to proteoglycans. J Biol Chem 2011; 286:1125-1133.
26. Ursini F, Davies KJ, Maiorino M, et al. Atherosclerosis: another protein misfolding disease? Trends Mol Med 2002; 8:370-374. (Pubitemid 34826722)
27. Benitez S, Villegas V, Bancells C, et al. Impaired binding affinity of electronegative low-density lipoprotein (LDL) to the LDL receptor is related to nonesterified fatty acids and lysophosphatidylcholine content. Biochemistry 2004; 43:15863-15872. (Pubitemid 39665085)
28. Avogaro P, Bon GB, Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis 1988; 8:79-87. (Pubitemid 18049179)
29. Sevanian A, Hwang J, Hodis H, et al. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol 1996; 16:784-793. (Pubitemid 26179367)
30. Oorni K, Hakala JK, Annila A, et al. Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans. J Biol Chem 1998; 273: 29127-29134. (Pubitemid 28507611)
31. Liu Y, Atkinson D. Immuno-electron cryo-microscopy imaging reveals a looped topology of apoB at the surface of human LDL. J Lipid Res 2011; 52:1111-1116.
32. Benitez S, Sanchez-Quesada JL, Lucero L, et al. Changes in low-density lipoprotein electronegativity and oxidizability after aerobic exercise are related to the increase in associated nonesterified fatty acids. Atherosclerosis 2002; 160:223-232. (Pubitemid 34076658)
33. Gaubatz JW, Gillard BK, Massey JB, et al. Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). J Lipid Res 2007; 48:348-357. (Pubitemid 46220601)
34. Jayaraman S, Gantz DL, Gursky O. Effects of phospholipase A(2) and its products on structural stability of human LDL: relevance to formation of LDL-derived lipid droplets. J Lipid Res 2011; 52:549-557.
35. Segrest JP, Jones MK, De Loof H, Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 2001; 42:1346-1367. (Pubitemid 34007665)
36. Bancells C, Villegas S, Blanco FJ, et al. Aggregated electronegative low density lipoprotein in human plasma shows a high tendency toward phos-pholipolysis and particle fusion. J Biol Chem 2010; 285:32425-32435.
37. Benitez S, Sanchez-Quesada JL, Ribas V, et al. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation 2003; 108:92-96. (Pubitemid 36859026)
38. Bancells C, Canals F, Benitez S, et al. Proteomic analysis of electronegative low-density lipoprotein. J Lipid Res 2010; 51:3508-3515.
39. Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 2000; 25:95-98. (Pubitemid 30122416)
40. Wyatt AR, Wilson MR. Identification of human plasma proteins as major clients for the extracellular chaperone clusterin. J Biol Chem 2010; 285:3532-3539.
41. Pettersson C, Karlsson H, Stahlman M, et al. LDL-associated apolipoprotein J and lysozyme are associated with atherogenic properties of LDL found in type 2 diabetes and the metabolic syndrome. J Intern Med 2011; 269:306-321.
42. Sanchez-Quesada JL, Vinagre I, Juan-Franco ED, et al. Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution. Am J Cardiol 2012; 110: 67-71.
43. Yerbury JJ, Stewart EM, Wyatt AR, Wilson MR. Quality control of protein folding in extracellular space. EMBO Rep 2005; 6:1131-1136. (Pubitemid 41741695)
44. Holopainen JM, Medina OP, Metso AJ, Kinnunen PK. Sphingomyelinase activity associated with human plasma low density lipoprotein. J Biol Chem 2000; 275:16484-16489. (Pubitemid 30398870)
45. Kinnunen PK, Holopainen JM. Sphingomyelinase activity of LDL: a link between atherosclerosis, ceramide, and apoptosis? Trends Cardiovasc Med 2002; 12:37-42. (Pubitemid 34048709)
46. Oorni K, Pentikainen MO, Ala-Korpela M, Kovanen PT. Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J Lipid Res 2000; 41:1 703-1714.
47. Boren J, Olin K, Lee I, et al. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest 1998; 101:2658-2664. (Pubitemid 28294574)
48. Flood C, Gustafsson M, Richardson PE, et al. Identification of the proteoglycan binding site in apolipoprotein B48. J Biol Chem 2002; 277:32228-32233. (Pubitemid 34969038)
49. Rabbani N, Godfrey L, Xue M, et al. Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes 2011; 60:1-8.